Neuroplasticity and ALS: What the Latest Research Actually Shows

Amyotrophic lateral sclerosis — ALS — is one of the most challenging diseases in neurology. It progressively damages the motor neurons that control voluntary movement, and there is currently no cure. But research into how the brain adapts, resists, and reorganizes in the face of ALS is producing important findings, and reshaping how scientists and clinicians think about the role neuroplasticity plays in progressive disease.

This article explains what ALS is, what the latest research actually shows about neuroplasticity in ALS, and why understanding the limits and possibilities of the brain's adaptive capacity matters for patients, caregivers, and the future of care.

N P A Q U I C K R E A D

• ALS is a progressive motor neuron disease that gradually damages the neurons controlling voluntary movement.

• Neuroplasticity in ALS is real but limited — the brain does attempt to reorganize, but it cannot outpace the ongoing loss of motor neurons.

• The role of neuroplasticity in ALS is different from stroke or brain injury — in progressive disease, it primarily supports compensation and preservation of function, not full recovery.

• Emerging research on brain-computer interfaces (BCIs), vagus nerve stimulation, and cognitive-motor training is producing meaningful results for maintaining independence, communication, and quality of life.

• The honest message: neuroplasticity does not reverse ALS — but understanding it is opening new avenues for supporting people living with the disease

What Is ALS?

ALS — amyotrophic lateral sclerosis — is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Specifically, it damages motor neurons — the specialized cells that carry signals from the brain to the muscles that produce voluntary movement. As these neurons deteriorate, muscles progressively weaken, waste, and

lose function.

According to the National Institute of Neurological Disorders and Stroke (NINDS), ALS causes progressive loss of both upper motor neurons (in the brain) and lower motor neurons (in the spinal cord). Roughly 1 in 300 people will receive an ALS diagnosis in their lifetime, and U.S. military veterans are more than twice as likely to be diagnosed as the general population (I AM ALS; NIH).

Common Early Signs

• Muscle twitching in the arm, leg, shoulder, or tongue

• Muscle weakness affecting an arm, leg, neck, or diaphragm

• Tight and stiff muscles (spasticity)

• Difficulty gripping objects, buttoning clothing, or writing

• Slurred speech or difficulty forming words

• Difficulty chewing or swallowing (dysphagia)

• Muscle cramps

Life Expectancy and Progression

The average life expectancy after diagnosis is two to five years (NINDS; NIH), though there is significant individual variability. About 10% of people with ALS live more than 10 years, and a small number live substantially longer. Most people with ALS ultimately die from respiratory failure. In some patients, ALS is associated with cognitive or behavioral changes, and there is a recognized overlap with frontotemporal dementia (FTD) — the two conditions are now understood to share genetic and biological features.

Is There a Cure?

There is currently no cure for ALS and no treatment that reverses its progression. FDA-approved medications (including riluzole, edaravone, and more recently tofersen for a specific genetic form) can modestly slow progression or extend survival, but they do not stop the disease. Multidisciplinary specialty care — combining neurology, physical and occupational therapy, respiratory support, nutrition, and speech-language therapy — is associated with improved survival and quality of life (Rooney et al., Journal of Neurology, Neurosurgery & Psychiatry, 2015).

What Is Neuroplasticity in the Context of ALS?

Neuroplasticity is the brain's ability to reorganize itself — forming new neural connections, strengthening existing ones, and adapting in response to experience, injury, or disease. It is why the brain can recover function after stroke, learn new skills throughout life, and adapt to changing environments.

In ALS, the question is different from stroke or traumatic brain injury. Those conditions involve a one-time event that healthy neurons can potentially reorganize around. ALS involves the ongoing, progressive loss of the specialized motor neurons themselves. The brain does attempt to adapt — but it is trying to reorganize around a target that

keeps shrinking.“Neuroplasticity in ALS is real, but its role is different. It is not about recovery in the way we describe stroke recovery. It is about compensation, preservation, and helping the nervous system get the most out of the circuits that remain.”— Adapted from published perspectives on neuroplasticity in neurodegenerative disease

What the Latest Research Actually Shows

Research over the past decade has produced a more nuanced picture of neuroplasticity in ALS. The findings are neither as pessimistic as older assumptions ("nothing can be done") nor as optimistic as some popular framings suggest ("the brain can just rewire around it").

Here is what the science supports.

1. The ALS Brain Does Attempt to Reorganize

Functional MRI and neuroimaging studies have documented that as motor neurons are lost, the brain often recruits additional or adjacent motor and premotor regions to preserve movement. Researchers have observed increased activation in areas near affected motor cortex regions, and in some cases involvement of the opposite hemisphere. This is real neuroplasticity — the nervous system attempting to compensate for progressive loss.

2. But This Reorganization Has Limits — and Can Sometimes Be Maladaptive

Research also shows that not all reorganization in ALS is beneficial. Some observed changes appear to reflect the disease process itself rather than helpful compensation, and in certain contexts brain reorganization can be maladaptive — changes that don't restore function and may even accelerate certain symptoms. Modern ALS research distinguishes carefully between compensatory plasticity (helpful) and disease-driven plasticity (not helpful). This is an important nuance often missed in popular coverage.

3. Brain-Computer Interfaces Are Advancing Rapidly

Some of the most promising recent research involves brain-computer interfaces (BCIs) — devices that read brain signals and translate them into communication or control of external devices. A 2026 review in Frontiers in Neuroscience documented that BCI use appears to boost neuronal activity in brain regions involved in movement and language, and that ongoing engagement with a BCI may help preserve neural activity in critical brain regions —

potentially delaying cortical degeneration caused by disuse (Kim et al., 2025). Recent trials of high-density BCIs have restored communication for people with ALS at speeds of 30+ words per minute.

4. Cognitive-Motor Training and Rehabilitation Retain a Role

Structured cognitive-motor training programs — exercises that engage the brain and body together, such as adapted physical therapy, speech therapy, and cognitive stimulation — can support neural circuits and slow functional decline.While these do not stop the underlying disease, they help preserve function longer than passivity would.

5. Combined Approaches Are the Frontier

The most promising research direction combines disease-modifying medications with neuroplasticity-supportive interventions. Emerging strategies include vagus nerve stimulation paired with rehabilitation (already FDA-approved for stroke via Vivistim, and being studied in other conditions), non-invasive brain stimulation like TMS, and assistive

technologies that reduce cognitive load while preserving engagement. The principle: neuroplasticity is most effective when combined with the treatments that address the disease itself.

Why This Matters for Care and Quality of Life

Understanding neuroplasticity in ALS reframes what supportive care can accomplish. Even without a cure, interventions that support neural adaptation can meaningfully affect the trajectory of daily life.

• Preserving communication through speech therapy, augmentative communication devices, and BCIs — keeping people connected to family, community, and self-expression.

• Maintaining mobility as long as possible through targeted physical therapy and assistive technology.

• Supporting cognitive engagement through structured mental activity, social connection, and meaningful work.

• Enabling participation and autonomy through eye-tracking systems, adaptive technology, and BCI-based control of environment and communication.

Every one of these preserves what neurologists sometimes call “the person inside the disease” — the identity, relationships, and dignity that outlast changes in physical function.

Neuroplasticity for ALS

Neuroplasticity in ALS is not a cure, and we do not present it as one. The disease continues to progress, and today's medical science cannot reverse motor neuron loss. What neuroplasticity offers is different: a scientific basis for the interventions that support compensation, preserve function, extend independence, and maintain the quality of daily

life for as long as possible. It also offers a research pathway. Ongoing work — on BCIs, on neuroprotection, on gene therapy, on the intersection of neuroplasticity with emerging disease-modifying treatments — is where the honest hope lives. The field is moving

forward, and understanding what neuroplasticity can and cannot do is part of moving with it.

Frequently Asked Questions

What is ALS in simple terms?

ALS — amyotrophic lateral sclerosis — is a progressive disease that damages the nerve cells (motor neurons) responsible for controlling voluntary muscle movement. As these neurons deteriorate, muscles gradually weaken and lose function. It's sometimes called Lou Gehrig's disease.

What are the first signs of ALS?

Early signs often include muscle weakness (especially in a hand, foot, arm, or leg), muscle twitching or cramps, difficulty gripping objects, slurred speech, or trouble swallowing. Symptoms are often subtle at first and can be mistaken for other conditions. A prompt neurological evaluation is important if concerns arise.

What is the life expectancy with ALS?

The average life expectancy after diagnosis is 2 to 5 years, though there is significant individual variability. About 10% of people with ALS live more than 10 years, and a small percentage live substantially longer. Progression rate varies widely from person to person.

Is there a cure for ALS?

Not currently. There is no treatment that reverses ALS. Several FDA-approved medications can modestly slow progression or extend survival, and specialized multidisciplinary care improves quality of life and survival. Research is active in gene therapy, neuroplasticity-supportive interventions, and BCIs.

Can neuroplasticity reverse ALS?

No. Neuroplasticity does not stop or reverse the underlying loss of motor neurons in ALS. What it can do is support compensation and preservation of function — helping the nervous system get the most out of the circuits that remain, and supporting the effectiveness of therapies, assistive technology, and communication tools.

How is neuroplasticity in ALS different from neuroplasticity in stroke?

In stroke, healthy brain regions often reorganize to take over functions lost due to a one-time injury — which is why substantial recovery is possible. In ALS, the specialized motor neurons themselves are progressively lost, so the brain cannot fully compensate the way it can after stroke. Neuroplasticity still plays a role in ALS — supporting compensation, preserving function, and enabling adaptive technology — but the outcome is different.

What causes ALS?

The cause is not fully understood. Roughly 10% of ALS cases are inherited (familial), with about 30 known genes implicated. The other 90% (sporadic ALS) result from a complex interplay of genetic susceptibility and environmental factors. U.S. military veterans have more than twice the risk of the general population, though the exact reasons are

still being studied.

What are brain-computer interfaces (BCIs) and can they help with ALS?

BCIs are devices that read brain signals and translate them into control of a computer, communication device, or robotic system. For people with ALS, BCIs are showing genuine promise for restoring communication as speech and movement are affected — recent trials have restored typing speeds of 30+ words per minute. Research also suggests

that ongoing BCI use may help preserve neural activity in key brain regions.

Where can I learn more about neuroplasticity and progressive disease?

The Neuroplasticity Alliance publishes ongoing, evidence-based resources on neuroplasticity, progressive disease, and neurological recovery. Visit npallies.org to explore our library, join our book club, or watch replays from the Rewiring Hope Summit.

References

National Institute of Neurological Disorders and Stroke (NINDS). (2025). Amyotrophic lateral sclerosis (ALS) fact sheet. U.S. National Institutes of Health.

I AM ALS. What Is ALS? (Lifetime risk and veteran risk statistics).

Kim, M. S., et al. (2025). Advancements in the application of brain-computer interfaces based on different paradigms in amyotrophic lateral sclerosis.

Frontiers in Neuroscience, 19, 1658315.

Rooney, J., Byrne, S., Heverin, M., et al. (2015). A multidisciplinary clinic approach improves survival in ALS: A comparative study of ALS in Ireland and

Northern Ireland. Journal of Neurology, Neurosurgery & Psychiatry, 86(5), 496–501.

Van den Berg, J. P., Kalmijn, S., Lindeman, E., et al. (2005). Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology, 65(8), 1264–

1267.

Wolfson, C., et al. (2023). Systematic review of the prevalence and incidence of amyotrophic lateral sclerosis. (Referenced in current ALS epidemiology

literature.)

Kleim, J. A., & Jones, T. A. (2008). Principles of experience-dependent neural plasticity: Implications for rehabilitation after brain damage. Journal of

Speech, Language, and Hearing Research, 51(1), S225–S239.

Murphy, T. H., & Corbett, D. (2009). Plasticity during stroke recovery: From synapse to behaviour. Nature Reviews Neuroscience, 10(12), 861–872.

Cramer, S. C., Sur, M., Dobkin, B. H., et al. (2011). Harnessing neuroplasticity for clinical applications. Brain, 134(6), 1591–1609